Ignite Creation Date:
2025-12-24 @ 10:48 PM
Ignite Modification Date:
2026-02-20 @ 11:49 PM
Study NCT ID:
NCT05506969
Status:
COMPLETED
Last Update Posted:
2025-07-29
First Post:
2022-08-10
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age
Sponsor:
Dynavax Technologies Corporation
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-08-09
Start Date Type:
ACTUAL
Primary Completion Date:
2023-10-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-04-26
Completion Date Type:
ACTUAL
First Submit Date:
2022-08-10
First Submit QC Date:
None
Study First Post Date:
2022-08-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-04-25
Results First Submit QC Date:
None
Results First Post Date:
2025-07-29
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-28
Last Update Post Date:
2025-07-29
Last Update Post Date Type:
ACTUAL